Wegovy (Semaglutide): Weight Loss Clinics & Cost Guide

Wegovy is a branded semaglutide injection made by Novo Nordisk and is the semaglutide product in the FDA reference file that is approved for chronic weight management. The file also notes an added cardiovascular risk-reduction indication in March 2024.

Like other semaglutide products, Wegovy is a GLP-1 receptor agonist that regulates appetite, slows gastric emptying, and improves insulin sensitivity. The difference is the labeled indication and dose pathway.

The STEP 1 trial, 2021 is the headline study in the reference file and reported average body-weight loss of 14.9% over 68 weeks versus 2.4% with placebo. The file also cites STEP 2 and STEP 3, which add more context around semaglutide performance in different patient groups and care settings.

Per the FDA label, Wegovy starts at 0.25 mg weekly, then escalates monthly until a 2.4 mg weekly maintenance dose. That step-up schedule is meant to improve tolerability while patients adjust to treatment.

The FDA reference lists Wegovy at roughly $1,300 to $1,400 per month retail without insurance.

Prices vary by pharmacy and location, and actual out-of-pocket cost may shift based on plan coverage and whether manufacturer savings programs apply.

Manufacturer savings programs may be available for some Wegovy prescriptions, but patients should confirm current details directly.

Prices vary by pharmacy, location, and clinic structure.

Wegovy is often compared with Ozempic because both use semaglutide, but Wegovy is the branded product with the weight-management indication in the FDA reference file.

It also sits in the broader semaglutide-versus-tirzepatide conversation, where weight-loss trial numbers, side effects, and coverage trade-offs all matter. The smarter comparison is usually product-label fit plus access, not just brand familiarity.